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ABSTRACT
The tumor suppressor microRNA-199b (miR-199b) is a negative SET regulator 
associated with poor outcome in some human cancers. However, its expression levels 
as well as potential biological and clinical significance in colorectal cancer (CRC) remain 
completely unexplored. The PP2A inhibitor SET has shown promising therapeutic and 
clinical implications in metastatic CRC (mCRC) but the molecular mechanisms underlying 
SET deregulation are currently unknown. We show here miR-199b downregulation 
in 4 out of 5 CRC SET-overexpressing cell lines and its inverse correlation with SET 
overexpression in CRC patients. Moreover, miR-199b led to PP2A activation through 
a direct SET inhibition, impaired cell viability and enhanced oxaliplatin sensitivity 
in CRC cells. MiR-199b was found downregulated in 25% of cases, and associated 
with lymph metastasis (p = 0.049), presence of synchronous metastasis at diagnosis 
(p = 0.026) and SET overexpression (p < 0.001). Furthermore, low miR-199b levels 
determined shorter overall (p < 0.001), progression-free survival (p = 0.003) and 
predicted clinical benefit to oxaliplatin treatment. The miR-199b prognostic impact 
was particularly evident in both younger and KRAS wild-type subgroups. Multivariate 
analyses confirmed its independent prognostic impact. Altogether, our results show 
that miR-199b is a tumor suppressor whose downregulation independently determines 
worse outcome and emerges as a potential contributing mechanism to inhibit PP2A 
via SET overexpression in a subgroup of mCRC patients.
INTRODUCTION
Colorectal cancer (CRC) represents the third most 
commonly diagnosed cancer and the fourth highest cause 
of cancer-related deaths worldwide [1]. Altough the CRC 
stage at diagnosis is the most predictive factor of clinical 
outcome, more than 70% of CRC cases newly diagnosed 
have a surgically resectable localized disease [2]. However, 
the remaining 20–30% of newly diagnosed CRC patients 
with unresectable distant metastasis together with a 
substantial proportion of cases who develop metachronous 
metastasis represents the subgroup of patients with worst 
outcome [3]. Therefore, it remains necessary to improve our 
molecular knowledge of CRC to identify alterations with 
both prognostic and predictive value of therapy efficacy to 
develop novel and more efficient targeted therapies.
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The protein phosphatase 2A (PP2A) is a well-known 
tumor suppressor that inhibits signaling pathways critical 
in human cancer [4, 5]. Several works highlighting the 
molecular and clinical significance of PP2A inhibition 
in CRC have been reported [6–9]. The protein SET 
is a potent endogenous PP2A inhibitor [10] involved 
in many cell functions [11–15] and a novel proposed 
target for anticancer therapy [16]. Interestingly, some 
evidences suggest that SET could be relevant in CRC 
progression [17]. In fact, our group has recently reported 
that SET deregulation determines poor outcome and 
defines a subgroup of metastatic CRC patients who could 
benefit from therapies containing PP2A activators [18]. 
MicroRNAs (miRs) are small non-coding RNAs that 
inhibit specific target genes by translation repression and 
they then can function as oncogenes or tumor suppresors 
in human cancer. MiR-199b is a SET inhibitor [19, 20] 
which has also been involved in acquired chemoresistance 
in chronic myeloid leukaemia or ovarian cancer [21, 22]. 
Moreover, miR-199b also functions as a tumor suppressor 
in medulloblastoma, hepatocellular carcinoma and breast 
cancers by affecting targets such as HEIS1, HIF1α 
or HER2 [23–25]. However, its status and potential 
significance in colorectal cancer is completely unknown.
In this report, we identified miR-199b 
downregulation as a common alteration with high 
clinical relevance that represents a potential contributing 
mechanism to SET overexpression in metastatic CRC 
patients. Interestingly, low miR-199b levels inversely 
correlated with SET expression and independently 
predicted shorter overall and progression-free survival 
defining a subgroup of metastatic CRC patients with very 
poor outcome candidate to be treated with SET/PP2A 
targeting drugs such as FTY720.
 RESULTS
MiR-199b is downregulated and affects SET 
expression and PP2A activation status in CRC 
cells
We quantified miR-199b in 5 different CRC cell 
lines, observing low miR-199b levels in 4 out of the 
5 CRC cell lines compared to normal colonic mucosa 
(Supplementary Table S1). Moreover, western blot 
analysis showed SET overexpression in the same 5 CRC 
cell lines (Figure 1A). The same normal controls were 
used in both experiments. We first performed luciferase 
assays to validate the role of miR-199b as a negative 
SET regulator in CRC. Transfection of pSET-3′UTRwt 
in SW480 cells ectopically expressing miR-199b showed 
decreased luciferase activity, indicating that miR-199b 
binds to the SET 3ʹUTR, negatively regulating its 
expression. Analysis using the same construct with the 
mutated miR-199b seed region showed no changes in 
luciferase activity, confirming that miR-199b directly binds 
to SET (Supplementary Figure S1). We next assessed the 
effects of miR-199b modulation on SET expression in 
SW480 cells using pre- and anti-microRNAs specific for 
miR-199b. As expected, we found decreased and increased 
SET levels in SW480 cells transfected with pre- and anti-
miR-199b, respectively (Figure 1B). Similar results were 
obtained using HT-29 cells (Supplementary Figure S2A). 
Due to SET is an endogenous PP2A inhibitor and 
miR-199b negatively regulates SET, we analyzed whether 
miR-199b deregulation could modulate PP2A in CRC 
cells. As expected, we observed PP2A activation in both 
SW480 and HT-29 cells after pre-miR-199b transfection. 
Although transfection with anti-miR-199b induced PP2A 
inhibition significance was only achieved in HT-29 cells. 
(Figure 1C and Supplementary Figure S2B). These results 
prompted us to analyze SET and miR-199b expression 
levels in a cohort of 97 patients with metastatic CRC. 
Patient characteristics are presented in Supplementary 
Table S2. Interestingly, a negative correlation was found 
between miR-199b and SET expression (Supplementary 
Figure S3). Moreover, significant lower miR-199b was 
significantly downregulated in the subgroup of patients 
with SET overexpression (Figure 1D), suggesting that 
altered expression miR-199b is a molecular mechanism 
that contributes to deregulate SET and PP2A activation 
status in CRC patients. 
MiR-199b impairs cell viability in a SET-dependent 
manner
To investigate its biological relevance as a potential 
tumor suppressor in CRC, we assessed the effects of 
miR-199b modulation on cell growth. Interestingly, 
we observed a reduced proliferation in SW480 cells 
transfected with a pre-miR-199b in comparison with 
those transfected with a negative control (Figure 2A). 
These results were confirmed with the HT-29 cell line 
(Supplementary Figure S4A). However, only slight effects 
on cell growth were found by anti-miR-199b in SW480 and 
HT-29 cells (Figure 2B and Supplementary Figure S4B). 
Of importance, we also observed that ectopic expression of 
SET significantly restored cell proliferation in SW480 cells 
transfected with pre-miR-199b (Figure 2C). Similar results 
were found in HT-29 cells (Supplementary Figure S4C). 
Altogether, these results would indicate that SET 
regulation is a key event which mediates miR-199b-
induced antitumor effects in CRC. 
MiR-199b sensitizes CRC cells to oxaliplatin and 
5-FU treatments
We next investigated the potential therapeutic 
role of miR-199b affecting sensitivity of CRC cells 
to standard chemotherapy drugs such as oxaliplatin 
and 5-FU. Interestingly, we found that miR-199b-
overexpressing SW480 cells showed higher sensitivity 
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to oxaliplatin treatment. These results were confirmed in 
the HT-29 cell line (Figure 3A). Similarly, we observed 
an enhanced sensitivity to 5-FU treatment in both 
SW480 and HT-29 cells transfected with pre-miR-199b 
(Figure 3B). In order to assess whether miR-199b 
affects oxaliplatin sensitivity through SET inhibition, 
we modulated SET expression in oxaliplatin treated 
SW480 and HT-29 cells ectopically expressing miR-199b. 
Interestingly, we observed that SET overexpression was 
able to restore oxaliplatin sensitivity (Supplementary 
Figure S5), suggesting that miR-199b regulates oxaliplatin 
sensitivity in CRC cells through a SET negative regulation. 
Prevalence of miR-199b downregulation in 
metastatic colorectal cancer and its association 
with molecular and clinical parameters 
In order to investigate whether miR-199b is 
deregulated in CRC patients, we analyzed miR-199b 
expression levels in a cohort of 97 patients with metastatic 
CRC. Mir-199b was found downregulated in 24 of 97 cases 
(24.7%). Patient characteristics are presented in Table 
S2. Interestingly, we found low miR-199b expression 
associated with development of lymph metastasis (37.9% 
versus 19.1%, p = 0.049), presence of synchronous 
metastasis at diagnosis (32.8% versus 12.8%, p = 0.026) 
and SET overexpression (53.1% versus 10.8%, p < 0.001). 
Association between miR-199b downregulation and 
molecular and clinical parameters are included in Table 1. 
Interestingly, we observed miR-199b dowregulated in 
17 out of 32 cases with SET overexpression, suggesting 
that low miR-199 is a relevant contributing alteration 
to deregulate SET in a subgroup of CRC patients. Of 
importance, these findings would also indicate the 
existence of alternative mechanisms in those SET-
overexpressing cases without miR-199b downregulation 
that should have to be elucidated in future studies.
Figure 1: MiR-199b downregulation is a common alteration in mCRC that regulates SET and PP2A activity (A) Western 
blot analysis showing SET expression levels in 5 CRC cell lines. (B) Western blot analysis showing SET expression in SW480 cells 
transfected with pre- or anti-miR-199b; (C) PP2A assays showing changes in PP2A activity in SW480 cells after transfection with pre- or 
anti-miR-199b. Data represented are mean of three independent experiments ± SD. *P < 0.05; **P < 0.01; (D) Box-plot showing miR-199b 
expression levels in patients with (N = 35) and without (N = 62) SET overexpression; N1-3: normal controls.
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Table 1: Association between miR-199b and clinical and molecular parameters in 97 patients 
with metastatic CRC
No. Cases High miR-199b (%) Low miR-199b (%) P
miR-199b 97 73 (75.3) 24 (24.7)  
Sex 97 73 24 0.830
 Male 67 50 (74.6) 17 (25.4)
 Female 30 23 (76.7) 7 (23.3)
Age 93 71 22 0.079
 < 70 44 30 (68.2) 14 (31.8)
 ≥ 70 49 41 (83.7) 8 (16.3)
ECOG 92 71 21 0.175
 0–2 75 60 (80) 15 (20)
 3–4 17 11 (64.7) 6 (35.3)
Site of primary tumor 97 73 24 0.524
 Colon 72 53 (73.6) 19 (26.4)
 Rectum 25 20 (80) 5 (20)
Synchronous metastasis 97 73 24 0.026
 No 39 34 (87.2) 5 (12.8)
 Yes 58 39 (67.2) 19 (32.8)
Number of metastatic sites 97 73 24 0.383
 1–2 89 68 (76.4) 21 (23.6)
 > 2 8 5 (62.5) 3 (37.5)
Liver metastasis 97 73 24 0.282
 No 33 27 (81.8) 6 (18.2)
 Yes 64 46 (71.9) 18 (28.1)
Lung metastasis 97 73 24 0.264
 No 68 49 (84.5) 19 (15.5)
 Yes 29 24 (82.8) 5 (17.2)
Lymph metastasis 97 73 24 0.049
 No 68 55 (80.9) 13 (19.1)
 Yes 29 18 (62.1) 11 (37.9)
Peritoneal metastasis 97 73 24 0.173
 No 78 61 (78.2) 17 (21.8)
 Yes 19 12 (63.2) 7 (36.8)
MSI 95 71 24 0.617
 No 89 66 (74.2) 23 (25.8)
 Yes 6 5 (83.3) 1 (16.7)
KRAS mutated 97 73 24 0.755
 No 58 43 (74.1) 15 (25.9)
 Yes 39 30 (76.9) 9 (23.1)
SET overexpression 97 73 24 < 0.001
No 65 58 (89.2) 7 (10.8)
Yes 32 15 (46.9) 17(53.1)
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Table 2: Univariate and multivariate Cox analyses in the cohort of 97 patients with mCRC
Univariate OS analysis Multivariate OS Cox analysis
HR
95% CI
Significance HR
95% CI
SignificanceLower Upper Lower Upper
Age 0.363 –
 < 70
 ≥ 70
1.00
1.29 0.74 to 2.25 – –
Gender 0.227 –
 Male
 Female
1.00
0.69 0.38 to 1.25 – –
Synchronous 0.096 –
 No
 Yes
1.00
1.66 0.91 to 3.02 – –
ECOG < 0.001 < 0.001
 0–2
 3–4
1.00 1.00
2.04 1.46 to 2.84 1.86 1.32 to 2.62
Number of metastatic sites 0.589 –
 1–2
 > 2
1.00
1.13 0.71 to 1.80 - –
MiR-199b downregulation < 0.001 0.003
 No
 Yes
1.00 1.00
3.46 1.88 to 6.38 2.72 1.41 to 5.24
Figure 2: MiR-199b impairs cell proliferation in CRC cells. MTS assay showing proliferation in SW480 cells transfected with 
pre-miR-199b (A), anti-miR-199b (B) or both SET and pre-miR-199b (C). Data represented are mean of three independent experiments ± SD. 
*P < 0.05; **P < 0.01.
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Clinical significance of miR-199b 
downregulation in metastatic colorectal cancer
We next investigated the potential clinical 
significance of miR-199b in mCRC. Clinical follow-up 
data were available for all the 97 patients included in the 
study, 67 male and 30 female, with a median of age of 
70 years (range: 40–89). The median OS of the global 
cohort was 25.3 months (95% confidence interval (CI): 
16.2–34.4). Of relevance, we found that those patients 
with low miR-199b expression showed a substantially 
shorter OS (median OS, 9.7 versus 30 months, p < 0.001) 
(Figure 4A) and PFS (median PFS, 8.6 versus 15.4 months, 
p = 0.003) (Figure 4B). 
We next stratified our cohort by KRAS mutation 
status, observing that miR-199b shows higher prognostic 
value in those patients with wild-type KRAS (median OS, 
8.6 versus 30 months, p = 0.001; median PFS, 5.8 versus 
15.4 months, p = 0.017) than in those cases with mutated 
KRAS (median OS, 13.5 versus 31.5 months, p = 0.032; 
median PFS, 8.7 versus 12.6 months, p = 0.080) (Figure 5). 
Moreover, miR-199b had significant prognostic value in 
OS in both subgroups of patients younger (median OS, 11.9 
versus 34.2 months, p = 0.003) and older than 70 years 
(median OS, 3.9 versus 26.9 months, p = 0.002). Although 
miR-199b predicted PFS in younger patients (median 
PFS, 9.7 versus 22.5 months, p = 0.009), significance 
in PFS was not achieved in the subgroup of elderly 
cases (median PFS, 3.8 versus 12 months, p = 0.119) 
(Supplementary Figure S6). Importantly, we observed 
that miR-199b downregulation was predictive of clinical 
benefit in those patients who received oxaliplatin-based 
chemotherapy (N = 39; p = 0.018) (Table S3). Of 
relevance, multivariate analysis demonstrated that ECOG 
and miR-199b downregulation have an independent 
prognostic value in our patient cohort in both OS (Table 2) 
and PFS (Supplementary Table S4). Additionally, we also 
analyzed the clinical significance of the PP2A inhibitor 
SET in our series. Immunohistochemical detection of 
SET is shown in Supplementary Figure S4. As expected, 
we confirmed that those patients with SET overexpressed 
showed a substantially shorter OS (median OS, 9.9 versus 
31.5 months, p < 0.001) and PFS (median PFS, 8.7 versus 
18.5 months, p = 0.009) (Supplementary Figure S7).
Furthermore, we analyzed miR-199b levels in 
primary and paired liver metastatic tissues from 10 CRC 
patients in order to investigate the potential significance 
of miR-199b in CRC cell metastasis development. 
We quantified miR-199b levels using Taqman Low 
Density Arrays (TLDAs) panel A (Applied Biosystems). 
Interestingly, we found lower miR-199b levels in liver 
metastatic tissues compared to their paired primary CRC 
tissues (p = 0.047) (Supplementary Figure S8). Altogether, 
these preliminary results suggest that miR-199b 
overexpression could be playing a role in CRC liver 
metastasis development. Finally, we analyzed the potential 
role of miR-199b deregulation on CD133 expression. We 
generated colonosphere-derived cells from the DLD-1, 
SW480 and HT-29 cell lines in which we observed CD133 
enrichment together with miR-199b downregulation 
(Supplementary Figure S9A). Although 3-fold increase in 
CD133 expression was observed in DLD-1 colonospheres 
no expression of miR-199b was detected, similarly than in 
DLD-1 parental cells (data not shown). In addition, CD133 
Figure 3: MiR-199b sensitizes CRC cells to oxaliplatin and 5-FU treatments. MTS assays showing the effect of miR-199b in 
the sensitivity to oxaliplatin (A) or 5-FU (B) in SW480 and HT-29 cells; Data represented are mean of three independent experiments ± SD. 
*P < 0.05; **P < 0.01.
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expression could be quantified in 64 CRC patients from 
our cohort with enough material available. Interestingly, 
we found that miR-199b and CD133 expression show a 
negative correlation (Supplementary Figure S9B), further 
suggesting that miR-199b deregulation could be affecting 
the CD133 expression status of CRC cells.
DISCUSSION
Our group has recently reported that SET 
overexpression is a marker of poor outcome in metastatic 
CRC patients which defines a subgroup of patients 
candidate to be treated with PP2A activating drugs [18]. 
However, how SET deregulation occurs in CRC remains 
fully unknown. We then evaluated molecular causes that 
could lead to SET overexpression in CRC, analyzing 
whether an altered expression of miR-199b could be 
involved in SET deregulation in CRC. Thus, we first 
quantified miR-199b in 5 CRC cell lines previously 
reported to have SET overexpression [6], observing 
that miR-199b was downregulated in 4 out of 5 cases. 
This observation together with the significant lower 
miR-199b expression found in the subgroup of SET-
overexpressing mCRC patients suggest a role of miR-199b 
in SET-mediated PP2A inhibition in CRC. This issue 
was further supported by the decrease in SET levels 
together with PP2A activation observed after miR-199b 
overexpression in CRC cell lines. Of note, the transfection 
with anti-miR-199b only promoted a slight reduction in 
PP2A activity probably due to the low basal miR-199b 
expression together with the SET overexpression status 
in both SW480 and HT-29 cells. These findings are in 
concordance with the fact that anti-miR-199b only induced 
a discrete increase of cell viability whereas miR-199b 
overexpression led to a marked reduction of cell growth. 
Moreover, the antitumor effects of miR-199b on cell 
growth is probably due to its role as negative SET regulator 
since the co-expression of miR-199b together with SET 
almost totally restored proliferation of CRC cells. Thus, 
miR-199b emerges as a novel tumor suppressor in CRC 
and its downregulation is a common alteration which 
contributes to PP2A inhibition in this disease.
Furthermore, miR-199b has been reported to be 
involved in acquired resistance to different antitumor 
therapies in human cancer such as imatinib in chronic 
myeloid leukemia [21], cisplatin in ovarian cancer [22] 
or trastuzumab in breast cancer [25]. Thus, we evaluated 
whether miR-199b could affect we observed that miR-199 
sensitize CRC cells to both oxaliplatin and 5-FU 
treatments. These findings are concordant with the fact 
that miR-199b negatively regulates SET, which has been 
described to modulate resistance to oxaliplatin and 5-FU 
treatments in CRC [18]. 
Despite some data in the literature describe miR-199b 
tumor suppressor roles in human cancer [20–25], nothing 
is known about its function in CRC. As indicated above, 
miR-199b has been reported to have prognostic value in 
hepatocellular and papillary thyroid carcinomas [24, 26]. 
Therefore and considering that miR-199b seems to be a 
molecular cause of SET overexpression in a subgroup of 
metastatic CRC patients, we hypothesized that miR-199b 
downregulation could have clinical impact in metastatic 
CRC. Of importance, miR-199b downregulation 
determined poor outcome and clinical benefit in those 
cases treated with oxaliplatin-based chemotherapy. This 
observation is in concordance with our in vitro results and 
further supports that miR-199b increases sensitivity to 
oxaliplatin in CRC cells. 
Figure 4: Clinical significance of miR-199b expression levels in metastatic CRC. Kaplan-Meier analyses of overall survival 
(A) and progression-free survival (B) in a cohort of 97 metastatic CRC patients.
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The KRAS mutation status is a key molecular factor 
in determining clinical benefit to cetuximab in CRC [27]. 
Therefore, we evaluated the clinical impact of miR-199b 
stratifying our cohort by the presence or not of KRAS 
mutations. Thus, we found that miR-199b downregulation 
showed higher prognostic impact in both OS and PFS 
in the KRAS wild type subgroup. These findings could 
have a potential therapeutic relevance since FTY720, a 
PP2A-activating drug that binds and blocks SET [28], has 
recently shown to resensitize CRC cell to cetuximab [29] 
and our results suggest that miR-199b could be playing a 
role via SET regulation.
In addition to SET, miR-199b has been reported to 
regulate other important targets such as HEIS1, HIF1α 
or HER2 in medulloblastoma, hepatocellular carcinoma 
and breast cancers [23–25]. Among those metastatic 
CRC patients without SET overexpression, we observed 
miR-199b downregulated in 7 out of 65 cases. Of 
importance, we observed that miR-199b downregulation 
determined substantially shorter OS in these patients 
(median OS, 11 versus 31.5 months, p = 0.052), although 
significance was not achieved probably by the low 
number of cases studied. Therefore, these observations 
would indicate a potential SET-independent prognostic 
value for miR-199b which needs to be further confirmed 
in forthcoming studies. Moreover, multivariate analyses 
demonstrated that miR-199b downregulation was an 
unfavorable independent factor associated with OS and 
PFS in mCRC, which further confirm its prognostic value 
in this disease.
In concordance with previous observations in 
medulloblastoma [23], we show lower miR-199b 
Figure 5: Prognostic impact of miR-199b in metastatic CRC patients stratified by KRAS mutation status. Kaplan-Meier 
analyses of overall survival and progression-free survival in KRAS wild type (N = 58) (A) and KRAS mutated subgroups (N = 39) (B).
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expression in CRC with metastatic disease. In their work, 
Garzia et al. provided relevant findings supporting that 
miR-199b downregulation in metastatic medulloblastoma 
cells was probably due to a methylation-based epigenetic 
regulation of this microRNA. Therefore, it remains 
necessary to evaluate in future investigations whether a 
similar mechanism of transcriptional regulation is also 
occurring in CRC cells. On the other hand, the Notch 
signaling pathway plays a relevant role in self-renewing 
processes and its inhibition has been described to decrease 
CD133+ tumor cells [23, 30]. Of importance, a negative 
feedback loop of regulation has been reported between 
miR-199b and HES1, a key Notch effector, then impairing 
the CD133+ stem cell-like subpopulation of tumor cells 
[23, 31]. Interestingly, we show here that miR-199b is 
downregulated after colonosphere generation, which are 
CD133-enriched cells. Moreover, we analyzed CD133 
in 64 metastatic CRC patients observing a negative 
correlation between CD133 and miR-199b. These results 
would indicate a potential relationship between miR-199b 
and CD133 in CRC cells that needs to be further explored 
in forthcoming studies.
In conclusion, our results show that miR-199 
downregulation is a frequent alteration in metastatic 
CRC that emerges as a novel therapeutic target and a 
contributing mechanism to SET overexpression in this 
disease. Interestingly, our findings indicate that miR-199 
downregulation is a common event that plays an 
oncogenic role in CRC cells. Moreover, this alteration has 
an independent prognostic value predicting poor outcome 
in metastatic CRC patients and could have important 
therapeutic implications via SET-dependent PP2A 
inhibition in metastatic CRC.
MATERIALS AND METHODS
Cell cultures and transfection
The human CRC cell lines SW480 (ATCC CCL-228), 
WiDr (ATCC CCL-218), DLD-1 (ATCC CCL-221), 
HT-29 (ATCC HTB-38) and SW620 (ATCC CCL-227) 
were purchased from American Type Culture Collection 
(ATCC). Authentication was done by the authors in all 
cases (LGC Standards). Cell lines were maintained in 
RPMI-1640 (Invitrogen) with 10% fetal bovine serum 
and were grown at 37ºC in a 5% CO2 atmosphere. 
Media were supplemented with penicillin G (100 U/ml), 
and streptomycin (0.1 mg/ml). Cells were treated with 
oxaliplatin (LOHP) (1 µM) (Sigma), 5-fluorouracil (5-FU) 
(1 µM) (Sigma) and FTY720 (10 µM) (Calbiochem) as 
previously reported [6, 9]. For transfection experiments, 
CRC cells were seeded in 6-well plates and transfected 
with 10 µl of Lipofectamine 2000 (Life Technologies) and 
2 µg of SET plasmidic vector or 20 nM of a miR-199b 
specific mirVana™ miRNA Mimic and Inhibitor 
(Ambion).
Patient samples
Primary colorectal tissues were surgical resection 
specimens from CRC tumors obtained from Fundacion 
Jimenez Diaz Biobank (BFJD, Madrid). The study 
comprised consecutive FFPE tumor samples of 97 patients 
with metastatic CRC that were retrospectively selected 
from 2001 to 2012 according to the following criteria: 
adenocarcinoma, operable disease, no neoadjuvant 
therapy, enough available tissue, clinical follow-up data 
and metastatic disease. TNM (Tumor, Node, Metastases) 
staging was classified using the 7th American Joint 
Committee on Cancer (AJCC) staging system for 
colorectal cancer. Clinical data were collected from 
medical clinical records by oncologists. KRAS mutational 
status was determined by Cobas KRAS Mutation Test kit 
(Roche Molecular Diagnostics) following manufacturer’s 
procedures. Tissue microarrays (TMA) were constructed. 
Representative areas of each tumor were carefully selected 
and three tissue cores (1 mm diameter) were obtained 
using a TMA workstation (T1000 Chemicon). Samples 
were taken anonymously. The ethical committee and 
institutional review board approved the project.
Western blot analysis
Protein extracts were isolated using TRIzol Reagent 
(Invitrogen) following manufacturer´s indications, 
clarified (12,000 × g, 15 min, 4ºC), denatured and 
subjected to SDS-PAGE and Western-blot. Antibodies 
used were rabbit polyclonal anti-SET (Abcam) and mouse 
monoclonal anti-βactin (Sigma). Proteins were detected 
with the appropriate secondary antibodies conjugated 
to alkaline phospatase (Sigma) by chemiluminescence 
using Tropix CSPD and Tropix Nitro Block II (Applied 
Biosystems).
Cell viability assay
Cell proliferation was measured in triplicate wells 
by MTS assay in 96-well plates using the CellTiter 
96 AQueous One Solution Cell Proliferation Assay 
(Promega), following the manufacturer´s indications.
PP2A phosphatase activity assay
PP2A assays were performed with cell lysates 
(50 μg) using a PP2A immunoprecipitation phosphatase 
assay kit (Millipore) as previously described [6].
Immunohistochemistry
Tissue sections (3 μm) were placed on plus charged 
glass slides. After deparaffinization in xylene and graded 
alcohols, heat antigen retrieval was performed in pH9 
EDTA-based buffer (Dako). Endogenous peroxidase was 
blocked by 0.03% hydrogen peroxide for 5 min. Slides 
Oncotarget40178www.impactjournals.com/oncotarget
were incubated with same primary antibody against SET 
as described for 60 minutes at room temperature, followed 
of appropriate anti-Ig horseradish peroxidase-conjugated 
polymer (Flex+, Dako). Sections were visualized with 
3,3ʹ-diaminobenzidine as a chromogen. All stainings were 
performed in a Dako Autostainer. Sections incubated with 
normal non-immunized rabbit immunoglobulins were 
used as negative controls. As positive control, a section of 
colorectal tumor with known expression of SET was used. 
SET antibody sensitivity (1:5000) had been calculated in a 
range of crescent dilutions of primary antibody. Specificity 
was confirmed in a set of paired fresh frozen and FFPE 
samples were processed by western blot and IHC. Only 
the membrane of epithelial cells, but not stromal cells, 
was evaluated for SET expression blinded to clinical data 
by two pathologists. A semiquantitative histoscore was 
calculated by estimation of the percentage of tumor cells 
positively stained with low, medium, or high staining 
intensity. The final score was determined after applying a 
weighting factor to each estimate. The following formula 
was used: histoscore = (low %) × 1 + (medium %) × 2 + 
(high %) × 3 and the results ranged from 0 to 300.
Quantification of miRNA expression levels
Total RNA was isolated using RecoverAll Total 
Nucleic Acid Isolation kit (Ambion) according to 
manufacturer’s instructions. Samples were reverse 
transcribed using the TaqManHMicroRNA Reverse 
Transcription Kit (Applied Biosystems) and mature 
miRNAs were quantified by quantitative real-time RT-PCR 
using TaqMan MicroRNA Assays (Applied Biosystems) 
specific for miR-199b (miR-199b-5p_000500) and U6B 
as internal control. Analysis of relative gene expression 
data was performed using the 2−ΔΔCT method [32]. The 
mean expression value of the global cohort (∆Ctcohort) 
was used to obtain the relative expression of each 
sample (∆∆Ct) and the fold change calculated as 2−ΔΔCT. 
Downregulation of miR-199b was considered when the 
expression in a sample was lower than mean minus SD 
of the patient cohort, corresponding to 0.378 fold change. 
Luciferase assays
Luciferase assays were done using the Dual-
Glo Luciferase Assay System (Promega) following the 
manufacturer´s intructions. SW480 cells were transfected 
with  20 nM of pre-miR-199b (Ambion) and a pmiR-Glo 
construct empty or including the SET 3´UTR with the wild 
type or mutated miR-199b seed region. Firefly luciferase 
activities were normalized to Renilla luciferase activities.
Colonospheres
We generated colonosphere-derived cells from 
DLD-1, SW480 and HT-29 cells using 6-well ultra-low 
attachment plates (Corning) and 10,000 cells per well. Cells 
were grown in serum-free DMEM/F12 supplemented with 
GlutMAX™-I (Gibco) 1% N2 (Gibco), 2% B27 (Gibco), 20 
ng/ml human FGF (Sigma) and 50 ng/ml EGF (Sigma). After 
7 days, plates were analyzed for colonosphere formation.
Statistical analysis
Statistical analyses were performed using SPSS 
20 for windows (SPSS Inc, Chicago Illinois). Overall 
survival (OS) was defined as the time from the date of 
surgery to the date of death from any cause or last follow-
up. Progression-free survival (PFS) was defined as the 
time from surgery until any primary, regional or distant 
recurrence, appearance of a secondary tumor or death. 
Kaplan-Meier method and survival comparisons were done 
with the log-rank test if proportional hazard assumption 
was fulfilled and Breslow otherwise. The Cox proportional 
hazards model was adjusted taking into consideration 
significant parameters in univariate analysis. A P-value 
less than 0.05 was considered statistically significant. 
Receiver operating curve (ROC) was used to determine 
the optimal cutoff point based on progression end point 
for SET expression as previously described method to 
calculate threshold values for biomarker analysis [33–35]. 
Following this criteria, high SET exprssion was considered 
when Hscore in tumor cells were equal or higher than 100. 
This work was carried out in accordance with Reporting 
Recommendations for Tumor Marker Prognostic Studies 
(REMARK) guidelines [36].
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